|
31 Jan 2023 |
Amjevita™ (adalimumab-atto), first biosimilar to Humira®, now available in the United States
|
|
31 Jan 2023 |
Anti-Bb Antibody (NM8074) Receives US FDA Clearance to Start Clinical Trial in Naïve aHUS Patients (Rare Disease)
|
|
31 Jan 2023 |
AmMax Bio Announces First Patients Dosed in Phase 2b Study of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
|
|
31 Jan 2023 |
Deka Biosciences Receives FDA Clearance of DK210 (EGFR) Investigational New Drug Application
|
|
30 Jan 2023 |
TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer
|
|
30 Jan 2023 |
Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
|
|
30 Jan 2023 |
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
|
|
27 Jan 2023 |
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
|
|
27 Jan 2023 |
Novartis provides update on Phase III STAND trial assessing crizanlizumab
|
|
27 Jan 2023 |
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
|
|
27 Jan 2023 |
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
|
|
27 Jan 2023 |
Update on US Food and Drug Administration Emergency Use Authorisation of Evusheld
|
|
27 Jan 2023 |
Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
|
|
27 Jan 2023 |
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
|
|
26 Jan 2023 |
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety
|
|
26 Jan 2023 |
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors
|
|
26 Jan 2023 |
Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
|
|
25 Jan 2023 |
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
|
|
25 Jan 2023 |
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
|
|
24 Jan 2023 |
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
|
|
24 Jan 2023 |
Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA
|
|
24 Jan 2023 |
AltruBio Announces First Patient Dosed in Phase 1 Trial of Next-Generation Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis
|
|
24 Jan 2023 |
Memo Therapeutics AG Announces Positive Phase I Data with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients
|
|
23 Jan 2023 |
Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis
|
|
20 Jan 2023 |
Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
|
